FDA Plans Three Risk Management-Related Guidances Under PDUFA III
Executive Summary
FDA's PDUFA III implementation plan will likely include three separate guidances to cover risk assessment, pharmacovigilance and risk management
You may also be interested in...
Drug Names Will Be Reviewed By FDA Within 90 Days Under PDUFA Timetable
FDA is establishing timetables for review of proprietary drug names as part of the next cycle of the Prescription Drug User Fee Act
Drug Names Will Be Reviewed By FDA Within 90 Days Under PDUFA Timetable
FDA is establishing timetables for review of proprietary drug names as part of the next cycle of the Prescription Drug User Fee Act
PhRMA Wary Of Large Simple Safety Trials, Tells FDA Not To Create Phase III+
Large simple safety studies should not become a routine pre-approval requirement, the Pharmaceutical Research & Manufacturers of America suggested during FDA's risk management public workshop April 9